Ezutromid

SUMMIT THERAPEU/S ADR (NASDAQ: SMMT) is conducting clinical trials for Duchenne muscular dystrophy, or DMD, and clostridium difficile infection, or CDI. The Analyst Janney analyst Yun Zhong initiated coverage of Summit Therapeutics with a Buy rating and $27 fair value estimate. The Thesis...

Sarepta Therapeutics Inc (NASDAQ: SRPT) forged a deal with Summit Therapeutics PLC (ADR) (NASDAQ: SMMT) to develop its utrophin pipeline in exchange for European rights and a Latin America option. Summit's stock soared higher by more than 100 percent following the announcement, but analysts...